Novel Agents and Future Prospects in the Treatment of Pancreatic Adenocarcinoma

摘要: Pancreatic adenocarcinoma is one of the most aggressive malignancies and fourth leading cause cancer-related mortality in United States. The majority patients are diagnosed at advanced stage with inoperable locally tumors or metastatic disease, palliative chemotherapy remains best therapeutic option for these patients. Despite intensive clinical pre-clinical research over last few years, combination anti-metabolite drug gemcitabine targeted agent erlotinib, considered standard care treatment patients, only minimal modest efficacy. Therefore, novel approaches currently under investigation an attempt to produce more definite results this fatal disease. In paper we summarize five interesting abstracts as presented 2013 American Society Clinical Oncology (ASCO) Annual Meeting. two studies, nimotuzumab, a monoclonal antibody against epidermal growth factor receptor (EGFR) (Abstract #4009) bavituximab, phosphatidylserine #4054) tested pancreatic cancer. Abstract #4012 study vismodegib, hedgehog pathway inhibitor, whereas #4035, toxicity efficacy sunitinib presented. Lastly, safety pimasertib, mitogen-activated protein kinase (MEK) combined #4041. Image:  Sophia Engastromenou Schliemann: founder " Sotiria ("Salvation") Hospital  (Athens, Greece) 1902.